Amyloid beta protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type.
We used the ELISA to measure the concentration of amyloid protein precursor with Kunitz type trypsin inhibitor domains (APPI) in CSF of dementia of the Alzheimer type (DAT) and examined the correlation of APPI with acetylcholinesterase (AChE) and somatostatin (SRIF). We found the APPI concentration in CSF of DAT to be significantly elevated compared with that of multi-infarct dementia and controls. We could significantly correlate APPI with AChE, but not correlate APPI with SRIF. The present results suggest that measurement of CSF APPI levels may be useful for diagnosis of DAT and the change of APPI may closely be associated with abnormality of acetylcholine system in DAT that has been reported.
Urakami
K
K
Division of Neurology, Faculty of Medicine, Tottori University, Japan.
Takahashi
K
K
Saito
H
H
Okada
A
A
Nakamura
S
S
Tanaka
S
S
Kitaguchi
N
N
Tokushima
Y
Y
Yamamoto
S
S
D000110:Acetylcholinesterase / Q000096:biosynthesis* / Q000302:isolation & purification / Q000378:metabolism; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000096:biosynthesis* / Q000378:metabolism / Q000493:pharmacokinetics; D007611:Aprotinin / Q000096:biosynthesis* / Q000378:metabolism / Q000493:pharmacokinetics; D001921:Brain / Q000378:metabolism; D004569:Electroencephalography; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007361:Intelligence Tests; D008297:Male; D018377:Neurotransmitter Agents / Q000378:metabolism; D011480:Protease Inhibitors / Q000276:immunology / Q000378:metabolism; D013004:Somatostatin / Q000134:cerebrospinal fluid; D013053:Spectrophotometry
D016229:Amyloid beta-Peptides; D018377:Neurotransmitter Agents; D011480:Protease Inhibitors; D013004:Somatostatin; D007611:Aprotinin; D000110:Acetylcholinesterase